MedTrace Logo

Efficacy of Platelet Rich Plasma on Pelvic Floor Muscle Strength and Recurrence Rate in Pelvic Organ Prolapse Surgery

NCT07746739 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2026-08-10

No results posted yet for this study

Summary

Pelvic organ prolapse (POP) is a common pelvic floor disorder associated with impaired quality of life and considerable postoperative recurrence following native tissue repair. Platelet-rich plasma (PRP) has emerged as a regenerative adjunct to improve tissue healing and surgical outcomes.

Objective: To evaluate the effect of adjuvant PRP on pelvic floor muscle A single-blind randomized controlled trial was conducted involving 40 women with stage II or higher POP who were randomly assigned to surgery with adjuvant PRP (n=20) or surgery alone (n=20). Pelvic floor muscle strength was assessed by perineometry, while anatomical outcomes were evaluated using the Pelvic Organ Prolapse Quantification (POP-Q) system 8 weeks postoperatively.

Conditions

  • Pelvic Organ Prolapse Vaginal Surgery
  • Pelvic Organ Prolapse
  • Platelet Rich Plasma Injection

Interventions

PROCEDURE

POP surgery adjunctive PRP

In this RCT participants receive POP surgery with adjunctive PRP injection in anterior vaginal wall approximately 1,5 cm below urethra at Pubocervical Fascia. Pelvic organ prolapse quantification and assessment of Levator ani muscle tone by using Eden Q biofeedback tool before surgery and 8 weeks postoperative

PROCEDURE

POP surgery adjunctive with placebo ( NaCl Injection)

During POP surgery placebo group receive NaCl injection in Pubocervicalis Fascia at 1,5 cm below urethra

Sponsors & Collaborators

  • Dr. M Djamil Hospital, Padang

    collaborator UNKNOWN

  • Andalas University

    lead OTHER

Principal Investigators

  • Yulia Margaretta Sari, MD · M Djamil Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
65 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-08-25
Primary Completion
2026-03-30
Completion
2026-04-30

Countries

  • Indonesia

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07746739 on ClinicalTrials.gov